Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

Kendra SweetRami KomrokjiEric PadronChristopher L CubittJoel G TurnerJunmin ZhouAlan F ListDavid A SallmanJana L DawsonDaniel M SullivanJulio ChavezBijal D ShahJeffrey E Lancet

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Selinexor plus 7+3 is a safe regimen for patients with newly diagnosed poor-risk AML and warrants further investigation in a larger clinical trial.

Keyphrases

acute myeloid leukemia
clinical trial
newly diagnosed
allogeneic hematopoietic stem cell transplantation
phase ii
double blind
high dose
randomized controlled trial
low dose
placebo controlled